CGEM Q1 2023 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q1 2023 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$63M

Net Income

-$58M

EPS (Diluted)

$-1.42

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$51M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$515M

Total Liabilities

$29M

Stockholders' Equity

$486M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$63M	-$33M	-92.2%
Net Income	-$58M	-$12M	-379.1%